Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives $106.20 Average Target Price from Analysts

by · The Markets Daily

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR – Get Free Report) have earned a consensus recommendation of “Buy” from the thirteen research firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, ten have assigned a buy rating and two have given a strong buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $106.20.

A number of research firms have issued reports on MNPR. Lake Street Capital initiated coverage on shares of Monopar Therapeutics in a research report on Tuesday, September 23rd. They set a “buy” rating and a $106.00 target price on the stock. Leerink Partners began coverage on Monopar Therapeutics in a research report on Monday, November 10th. They issued an “outperform” rating and a $115.00 price objective for the company. Raymond James Financial cut Monopar Therapeutics from a “strong-buy” rating to an “outperform” rating and reduced their price objective for the stock from $142.00 to $123.00 in a research report on Friday, November 14th. Wall Street Zen upgraded shares of Monopar Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday. Finally, Oppenheimer set a $115.00 price objective on Monopar Therapeutics and gave the company an “outperform” rating in a report on Thursday, October 2nd.

Check Out Our Latest Research Report on MNPR

Insider Transactions at Monopar Therapeutics

In other Monopar Therapeutics news, major shareholder Tactic Pharma Llc sold 550,229 shares of the stock in a transaction on Wednesday, September 24th. The shares were sold at an average price of $63.61, for a total value of $35,000,066.69. Following the completion of the sale, the insider owned 272,026 shares in the company, valued at $17,303,573.86. This trade represents a 66.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Monopar Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP bought a new stake in shares of Monopar Therapeutics during the 3rd quarter worth about $18,904,000. Vanguard Group Inc. boosted its stake in Monopar Therapeutics by 140.7% in the 3rd quarter. Vanguard Group Inc. now owns 208,218 shares of the company’s stock valued at $17,005,000 after purchasing an additional 121,729 shares during the period. Deerfield Management Company L.P. bought a new stake in shares of Monopar Therapeutics in the third quarter valued at about $13,048,000. TCG Crossover Management LLC acquired a new position in shares of Monopar Therapeutics in the third quarter valued at about $12,496,000. Finally, ADAR1 Capital Management LLC grew its position in shares of Monopar Therapeutics by 28.7% during the 3rd quarter. ADAR1 Capital Management LLC now owns 129,999 shares of the company’s stock worth $10,617,000 after purchasing an additional 29,025 shares in the last quarter. 1.83% of the stock is currently owned by institutional investors and hedge funds.

Monopar Therapeutics Stock Performance

Monopar Therapeutics stock opened at $67.70 on Monday. The business’s fifty day moving average is $82.52 and its two-hundred day moving average is $58.37. The firm has a market cap of $452.24 million, a P/E ratio of -19.68 and a beta of 1.46. Monopar Therapeutics has a 52 week low of $21.00 and a 52 week high of $105.00.

Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.02). On average, equities research analysts predict that Monopar Therapeutics will post -1.65 earnings per share for the current year.

Monopar Therapeutics Company Profile

(Get Free Report)

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

See Also